MAPK3 and cancer: Drug resistance is a major obstacle to cancer therapies; therefore, it is of pivotal importance to unveil the molecular mechanisms and the processes that sustain cancer cell survival in the course of anti-cancer treatments, such as p-4EBP1 and ERK1/2 in the case of PEL cells treated by DMF at low and high doses, respectively.